Jonathan Chang
Stock Analyst at Leerink Partners
(4.14)
# 1,584
Out of 5,073 analysts
553
Total ratings
37.9%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.29 | +173.97% | 1 | Jul 13, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $3.72 | - | 7 | Jun 2, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $11 | $0.8145 | +1,250.52% | 1 | Apr 27, 2026 | |
| REPL Replimune Group | Downgraded: Hold | $13 → $2 | $11.72 | -82.94% | 48 | Apr 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $194.28 | -24.34% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Reiterated: Buy | $24 → $37 | $25.83 | +43.24% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $7.69 | +121.07% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $16.40 | +89.02% | 1 | Feb 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $9.88 | +102.43% | 51 | Jan 13, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $15.59 | +53.94% | 19 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $24.20 | n/a | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $39.57 | n/a | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $0.4244 | n/a | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $3.59 | n/a | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.11 → $0.09 | $0.032 | n/a | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $3.57 | n/a | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $32.09 | n/a | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $25.16 | n/a | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.015 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $890.05 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $39.50 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0001 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.37 | n/a | 1 | Jun 1, 2022 |
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.29
Upside: +173.97%
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.72
Upside: -
Compass Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $11
Current: $0.8145
Upside: +1,250.52%
Replimune Group
Apr 13, 2026
Downgraded: Hold
Price Target: $13 → $2
Current: $11.72
Upside: -82.94%
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $194.28
Upside: -24.34%
Nanobiotix
Apr 1, 2026
Reiterated: Buy
Price Target: $24 → $37
Current: $25.83
Upside: +43.24%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $7.69
Upside: +121.07%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $16.40
Upside: +89.02%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $9.88
Upside: +102.43%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $15.59
Upside: +53.94%
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $24.20
Upside: n/a
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $39.57
Upside: n/a
Oct 10, 2025
Reiterated: Hold
Price Target: $8 → $6
Current: $0.4244
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $8 → $5
Current: $3.59
Upside: n/a
Aug 13, 2025
Reiterated: Hold
Price Target: $0.11 → $0.09
Current: $0.032
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $3.57
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $60
Current: $32.09
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $25.16
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.015
Upside: n/a
Jun 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $890.05
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $39.50
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0001
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: n/a
Current: $4.37
Upside: n/a